Allogeneic Anti-CD30 CAR-Epstein-Barr Virus-specific T-lymphocytes

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic human Epstein-Barr virus (EBV)-specific T-lymphocytes (EBVSTs) that have been genetically modified to express a chimeric antigen receptor (CAR) recognizing the tumor-associated antigen (TAA) cluster of differentiation 30 (CD30), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD30 CAR-EBVSTs specifically recognize and bind to CD30-expressing EBV-infected tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. EBV, a ubiquitous human herpes virus, is associated with various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.

**Synonyms:** - Allogeneic Anti-CD30 CAR EBV-specific T Lymphocytes - Allogeneic Anti-CD30 CAR-EBVSTs - Allogeneic CD30.CAR-EBVSTs